NCT04999631View on ClinicalTrials.gov

SADBE for Congenital Melanocytic Nevi

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions
Congenital Melanocytic Nevus
Interventions
DRUG

Squaric Acid Dibutyl Ester

Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.

DRUG

Ethanol Solution

Control

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER